FDA Grants Breakthrough Therapy and Fast Track Designations to Protara's TARA-002 for Pediatric Lymphatic Malformations
核心洞察
The FDA has granted both Breakthrough Therapy and Fast Track designations to TARA-002 for treating pediatric patients with macrocystic and mixed cystic lymphatic malformations (搜索).
TARA-002 was selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to accelerate manufacturing development and patient access.
The investigational cell-based therapy is derived from the same master cell bank as OK-432, which has been the standard of care in Japan for 30 years.
Protara Therapeutics announced that the U.S. Food and Drug Administration has granted both Breakthrough Therapy and Fast Track designations for TARA-002, the company's investigational cell-based therapy, for the treatment of pediatric patients with macrocystic and mixed cystic lymphatic malformations (搜索). Additionally, the FDA selected TARA-002 to participate in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program, which aims to support manufacturing development of products with expedited clinical development timeframes.
"Receiving these important FDA designations and invitation to participate in the CDRP program highlights the significant unmet need among pediatric patients with LMs and underscores our belief that TARA-002 could serve as a meaningful treatment option for this underserved patient population," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.
Regulatory Pathway Acceleration
The FDA's Breakthrough Therapy designation is designed to expedite the development and regulatory review of drugs or biologics that treat serious conditions where preliminary clinical evidence indicates the therapy may demonstrate substantial improvement on at least one clinically significant endpoint over available therapy. The Fast Track program facilitates development and expedites review of new drugs and biologics designed to treat serious conditions with unmet medical needs.
TARA-002 was previously granted Rare Pediatric Disease designation for the treatment of lymphatic malformations (搜索), adding to its regulatory advantages.
Manufacturing Development Support
The FDA created the CDRP Program to facilitate manufacturing development for therapies with compressed clinical development timeframes based on the anticipated clinical benefits of earlier patient access. The initiative promotes earlier and more structured engagement between sponsors and the FDA on manufacturing development strategies, and has led to increased collaboration that allows sponsors to confidently scale up manufacturing capacity while clinical development is ongoing.
TARA-002's acceptance into this program will involve manufacturing for both the company's lymphatic malformations (搜索) and non-muscle invasive bladder cancer (搜索) programs.
TARA-002 Development Background
TARA-002 is an investigational, genetically distinct strain of streptococcus pyogenes that is inactivated while retaining its immune-stimulating properties. The therapy was developed from the same master cell bank as OK-432, which was originally granted marketing approval by the Japanese Ministry of Health (搜索) for the treatment of lymphatic malformations (搜索) and has been the standard of care in Japan for 30 years.
OK-432 was studied in a large Phase 2 trial in lymphatic malformations (搜索) in over 500 patients with significant clinical success, providing clinical precedent for TARA-002's development approach.
Disease Burden and Clinical Need
Lymphatic malformations (搜索) are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Most lymphatic malformations are present in the head and neck region and are diagnosed in early childhood during the period of active lymphatic growth, with more than 50% detected at birth and 90% diagnosed before the age of three years.
The most common morbidities and serious manifestations of the disease include compression of the upper aerodigestive tract, including airway obstruction requiring intubation and possible tracheostomy dependence; intralesional bleeding; impingement on critical structures, including nerves, vessels and lymphatics; recurrent infection; and cosmetic and other functional disabilities.
Next Steps
Protara expects to meet with the FDA to define the path to registration for TARA-002 in lymphatic malformations (搜索) in the first half of this year. The company is currently evaluating TARA-002 in a Phase 2 trial in pediatric patients with lymphatic malformations, as well as an ongoing Phase 2 trial in non-muscle invasive bladder cancer (搜索) patients with carcinoma in situ (搜索) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (搜索).